Vnitr Lek 2005, 51(6):676-680

Results of multi-centre monitoring of sibutramine treatment in obese diabetic patients in Czech Republic

A. Šmahelová

Klinika gerontologická a metabolická Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Luboš Sobotka, CSc.

Sibutramine is a very effective antiobesitic drug in the present. It has weight reducing, global metabolic and antidiabetic effects. To verify and to get the experiences with practical use of sibutramin in Type 2 diabetics in the Czech Republic was the purpose of the clinical observation MERIDIOS I.

Patients and methods:
499 diabetics (average age 52.4 ± 9,5 years) were included, to the statistical evaluation after 3 months of the therapy Wilcoxon rank sum test was used. 308 (61,7%) diabetics took oral antidiabetic agents. 424 (83%) diabetics used antihypertensive drugs, 384 (75%) hypolipidemic agents. 275 (55.1%) diabetics took sibutramine in the dose 10 mg once a day, 224 (44.9%) diabetics in the dose 15 mg once a day.

Results:
The average weight loss was 6.1 kg (p < 0.001). Waist circumference diminished about 4.7 cm (p < 0.001), glycosylated hemoglobin about 0.75% (p < 0.001), systolic blood pressure about 5.2 mm Hg (p < 0.001), diastolic blood pressure about 3.1 mm Hg (p < 0.001) in average. The daily dosage of oral antidiabetic agents diminished in 33.1% of all included diabetics. Any serious adverse events of sibutramine were recorded.

Conclusion:
Significant weight loss, diminished waist circumference and blood pressure, improvement of diabetes compensation and lower daily dose of oral hypoglycemic agents were observed in obese Type 2 diabetics after 3 months therapy with sibutramine in the dose 10 or 15 mg per day.

Keywords: diabetes mellitus type 2; sibutramin; obesity

Received: February 28, 2005; Accepted: April 5, 2005; Published: June 1, 2005  Show citation